Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Oral and intramuscular methylprednisolone are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]
Marketing Status approved; vet_approved
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 72647-331; 0781-5022; 80425-0230; 59746-003; 59762-0049; 63187-160; 71205-453; 0603-4593; 82094-402; 60722-1003; 64958-0084; 55289-649; 59762-4440; 63629-2218; 68001-557; 68001-560; 80425-0242; 22552-0029; 0009-0056; 45865-104; 59762-0050; 59762-0051; 60760-373; 63187-802; 65162-871; 68071-5221; 70121-1000; 59746-015; 65162-982; 68001-005; 68071-4028; 68084-149; 68788-4593; 71205-054; 72189-264; 82094-401; 45865-417; 50090-3094; 59746-002; 63629-2433; 68001-558; 68180-686; 69306-400; 70518-3622; 82094-403; 59746-001; 68071-2301; 68180-687; 70518-2982; 70771-1348; 70771-1349; 80425-0255; 0009-0073; 49999-153; 53002-3120; 63629-2226; 68001-559; 68180-685; 68180-688; 68382-917; 68382-918; 68382-919; 70771-1350; 80425-0231; 0904-6914; 49452-4686; 51552-0603; 0009-0020; 42806-400; 65162-984; 68180-689; 68382-916; 68788-8276; 69306-004; 70121-1001; 70771-1351; 76420-041; 82298-118; 76420-193; 82094-404; 82094-405; 51927-0201; 0009-0022; 65162-980; 68071-2745; 68788-7833; 0009-0038; 57582-011; 0009-0176; 57582-101
UNII X4W7ZR7023
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Graft versus host disease12.02.09.001; 10.02.01.0270.000064%Not Available
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.0050.000032%
Haematemesis24.07.02.011; 07.12.02.0020.000096%Not Available
Haematochezia24.07.02.012; 07.12.02.0030.000208%Not Available
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemolysis01.06.04.002--
Haemolytic anaemia01.06.03.0020.000080%Not Available
Haemorrhage subcutaneous23.06.07.002; 24.07.06.0100.000048%Not Available
Haemorrhoids07.15.03.001; 24.10.02.002--
Hallucination19.10.04.0030.000256%
Hallucination, auditory19.10.04.0040.000048%Not Available
Hallucination, visual19.10.04.0070.000112%Not Available
Headache17.14.01.0010.002606%
Hemiparesis17.01.04.0010.000064%
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000032%Not Available
Hepatic failure09.01.03.0020.000160%
Hepatic function abnormal09.01.02.0010.000192%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000032%Not Available
Hepatitis09.01.07.0040.000400%Not Available
Hepatitis acute09.01.07.0050.000080%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.000032%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000048%Not Available
Hepatocellular injury09.01.07.0080.000160%Not Available
Hepatomegaly09.01.05.0010.000032%Not Available
Hiccups22.12.01.001; 07.01.06.0090.000195%
Hirsutism23.02.04.001; 05.05.01.005--
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.0040.000048%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene